Literature DB >> 8137155

Inhibition of opiate tolerance by non-competitive N-methyl-D-aspartate receptor antagonists.

K A Trujillo1, H Akil.   

Abstract

Our laboratory and others have previously reported that the non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist, MK-801, interferes with the development of tolerance to the analgesic effects of morphine. The present studies were performed in order to further characterize the role of NMDA receptors in opiate tolerance. The results demonstrate that opiate tolerance is inhibited rapidly, and at low doses, by four different non-competitive NMDA receptor antagonists (MK-801, ketamine, dextrorphan and phencyclidine), suggesting that this inhibition results from blockade of NMDA receptors rather than from the 'side-effect' of a particular drug. The NMDA antagonists were found to inhibit the development but not the expression of opiate tolerance; i.e. they were able to prevent but not reverse tolerance. Finally, the results suggest that NMDA receptor antagonists do not interfere with associative tolerance; instead it appears that these drugs may specifically inhibit non-associative tolerance. It thus appears that NMDA receptors may have a fundamental role in the development of opiate tolerance, and that non-competitive NMDA receptor antagonists may be effective adjuncts to opiates in the treatment of chronic pain.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8137155     DOI: 10.1016/0006-8993(94)91538-5

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  41 in total

1.  Blockade and reversal of spinal morphine tolerance by peptide and non-peptide calcitonin gene-related peptide receptor antagonists.

Authors:  K J Powell; W Ma; M Sutak; H Doods; R Quirion; K Jhamandas
Journal:  Br J Pharmacol       Date:  2000-11       Impact factor: 8.739

2.  Functionally differentiating two neuronal nitric oxide synthase isoforms through antisense mapping: evidence for opposing NO actions on morphine analgesia and tolerance.

Authors:  Y A Kolesnikov; Y X Pan; A M Babey; S Jain; R Wilson; G W Pasternak
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

Review 3.  Roles of reactive oxygen and nitrogen species in pain.

Authors:  Daniela Salvemini; Joshua W Little; Timothy Doyle; William L Neumann
Journal:  Free Radic Biol Med       Date:  2011-01-28       Impact factor: 7.376

4.  Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain.

Authors:  C Y Yang; C S Wong; J Y Chang; S T Ho
Journal:  Can J Anaesth       Date:  1996-04       Impact factor: 5.063

Review 5.  Mu opioids and their receptors: evolution of a concept.

Authors:  Gavril W Pasternak; Ying-Xian Pan
Journal:  Pharmacol Rev       Date:  2013-09-27       Impact factor: 25.468

Review 6.  Combined opioid-NMDA antagonist therapies. What advantages do they offer for the control of pain syndromes?

Authors:  Z Wiesenfeld-Hallin
Journal:  Drugs       Date:  1998-01       Impact factor: 9.546

7.  Stabilization of morphine tolerance with long-term dosing: association with selective upregulation of mu-opioid receptor splice variant mRNAs.

Authors:  Jin Xu; Andrew J Faskowitz; Grace C Rossi; Mingming Xu; Zhigang Lu; Ying-Xian Pan; Gavril W Pasternak
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-22       Impact factor: 11.205

Review 8.  Endogenous Opioids at the Intersection of Opioid Addiction, Pain, and Depression: The Search for a Precision Medicine Approach.

Authors:  Michael A Emery; Huda Akil
Journal:  Annu Rev Neurosci       Date:  2020-02-28       Impact factor: 12.449

9.  NMDA receptor antagonists inhibit opiate antinociceptive tolerance and locomotor sensitization in rats.

Authors:  Ian A Mendez; Keith A Trujillo
Journal:  Psychopharmacology (Berl)       Date:  2007-11-10       Impact factor: 4.530

10.  The NMDA receptor antagonist dizocilpine (MK-801) stereoselectively inhibits morphine-induced place preference conditioning in mice.

Authors:  E Del Pozo; M Barrios; J M Baeyens
Journal:  Psychopharmacology (Berl)       Date:  1996-06       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.